{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=5", "query": { "intervention": "Matching Oral Placebo", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 3455, "total_pages": 346, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:38:00.758Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02935673", "title": "Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Viruses" ], "interventions": [ { "name": "lumicitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2016-10-25", "completion_date": "2018-07-17", "has_results": true, "last_update_posted_date": "2019-12-24", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 10, "location_summary": "Fresno, California • Orange, California • Stanford, California + 7 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Eustis", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935673" }, { "nct_id": "NCT05556824", "title": "Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Reflux" ], "interventions": [ { "name": "MHS-1031", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Microbiome Health Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 255, "start_date": "2023-03-03", "completion_date": "2026-05-27", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Los Angeles, California • Lake City, Florida + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lake City", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05556824" }, { "nct_id": "NCT02301988", "title": "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 151, "start_date": "2015-02-17", "completion_date": "2017-08-02", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 16, "location_summary": "Tucson, Arizona • Santa Barbara, California • Lakewood, Colorado + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301988" }, { "nct_id": "NCT04820842", "title": "A Study of TAK-994 in Adults With Narcolepsy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Narcolepsy Type 1 (NT 1)" ], "interventions": [ { "name": "TAK-994", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 26, "start_date": "2021-04-30", "completion_date": "2021-11-03", "has_results": true, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 35, "location_summary": "Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 29 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04820842" }, { "nct_id": "NCT03049735", "title": "LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 388, "start_date": "2017-04-26", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 76, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049735" }, { "nct_id": "NCT03152591", "title": "Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycystic Ovary Syndrome" ], "interventions": [ { "name": "LIK066", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 29, "start_date": "2017-07-24", "completion_date": "2018-06-25", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 2, "location_summary": "Springfield, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "Springfield", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152591" }, { "nct_id": "NCT05602818", "title": "A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Soticlestat 300 mg", "type": "DRUG" }, { "name": "Soticlestat 600 mg", "type": "DRUG" }, { "name": "Soticlestat 900 mg", "type": "DRUG" }, { "name": "Alprazolam", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 100, "start_date": "2022-11-15", "completion_date": "2023-07-07", "has_results": true, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602818" }, { "nct_id": "NCT05027997", "title": "Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blepharospasm", "Dystonia" ], "interventions": [ { "name": "Dipraglurant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Addex Pharma S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 15, "start_date": "2021-10-06", "completion_date": "2022-11-27", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027997" }, { "nct_id": "NCT06491550", "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD4144- Part A", "type": "DRUG" }, { "name": "Placebo- Part A", "type": "DRUG" }, { "name": "AZD4144- Part B", "type": "DRUG" }, { "name": "Placebo- Part B", "type": "DRUG" }, { "name": "Rosuvastatin and Furosemide- Part C", "type": "DRUG" }, { "name": "Rosuvastatin, Furosemide, and AZD4144 Part C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 91, "start_date": "2024-07-15", "completion_date": "2025-06-11", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06491550" }, { "nct_id": "NCT02410278", "title": "Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "dimethyl fumarate", "type": "DRUG" }, { "name": "montelukast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2015-03-12", "completion_date": "2017-04-27", "has_results": true, "last_update_posted_date": "2020-03-31", "last_synced_at": "2026-10-14T04:38:00.758Z", "location_count": 50, "location_summary": "Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410278" } ] }